We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Dako Enters into an Additional Collaboration with Amgen
News

Dako Enters into an Additional Collaboration with Amgen

Dako Enters into an Additional Collaboration with Amgen
News

Dako Enters into an Additional Collaboration with Amgen

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Dako Enters into an Additional Collaboration with Amgen"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Dako has announced that it has entered into a new collaboration agreement with Amgen Inc. on the development of a diagnostic test for an Amgen cancer drug candidate in clinical development.

“It is Dako’s mission to fight cancer. Hence, we are pleased to be chosen as Amgen’s partner once again for the development of companion diagnostics linked to Amgen’s investigational targeted therapies,” says Lars Holmkvist, Dako’s chief executive officer.

In January 2012, Dako announced a collaboration agreement with Amgen Inc. introducing a new business model which supports the concurrent development of drug and diagnostics for a rare but deadly cancer - something that up to this point has been difficult to achieve in the industry.

“This new collaboration with Amgen underlines Dako’s commitment to advance personalized medicine in cancer treatment as the selection of patients most likely to benefit from a specific treatment will increase the probability of therapeutic success for cancer patients suffering," Lars Holmkvist adds.

Today’s news comes on the heels of several pharmDx™ collaborative agreements recently announced by Dako.

The demand for personalized medicine is increasing with the recognition that it may provide a way to improve patient care and manage healthcare costs by targeting treatments to individuals more likely to benefit from specific therapies.

Advertisement